Do Novel Workflows Increase Regulatory Scrutiny?
Source: Bioprocess Online
David Bruehlmann, Ph.D. addresses continuous manufacturing in biopharma from the regulator’s perspective before sharing his view of where the technology is going next in this segment of the Bioprocess Online Live event Process Optimization or Full-Scale Automation. We discuss the chasm between the positive perception of continuous versus actual adoption, and discuss upcoming Bioprocess Online Live event programming.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more